NEXT GENeSYS

NextGenESys Biotherapeutics is a biotechnology company focused on developing next-generation gene therapies for the treatment of cancer. The company utilizes its proprietary Engineered Systems (ESys) platform to create viral vectors capable of systemic delivery, overcoming traditional barriers like neutralization by the immune system. Their lead programs, NGS-101 and NGS-102, aim to deliver therapeutic genes such as p53 and IL-12 directly to solid tumors to induce cell death and stimulate a robust anti-tumor immune response. By enabling repeat systemic administration, NextGenESys seeks to treat metastatic disease and hard-to-reach tumors that are currently underserved by local injection methods. The company's technology represents a significant advancement in the field of oncology by combining the precision of gene therapy with the reach of systemic medicine.